Avoro Capital Advisors Adds $124M in Definium Therapeutics, Inc. ($DFTX)

Avoro Capital Advisors has taken a new position in Definium Therapeutics, Inc. (NASDAQ:DFTX). The investment firm acquired 5 million shares, valued at about $123.75 million. This move was disclosed in Avoro's latest 13F filing with the SEC, reflecting its holdings as of the reporting period.

What Changed in Avoro Capital Advisors' Definium Therapeutics Position

Avoro Capital Advisors' new position in Definium Therapeutics consists of 5 million shares, marking a substantial entry into the company's stock. This acquisition, with a cost basis of $17.40 per share, suggests a strong interest in the biotechnology firm's potential.

Other Institutional Activity in Definium Therapeutics

In addition to Avoro, several other institutional investors have shown interest in Definium Therapeutics. BlackRock, Inc. added 8,480,230 shares, ending with 8,480,230 shares valued at approximately $160.28 million. Driehaus Capital Management LLC reduced its stake by 625,313 shares, leaving it with 5,911,889 shares worth about $111.73 million. Janus Henderson Group PLC acquired 3,556,041 shares, holding a total of 3,556,041 shares valued at $67.23 million. Deep Track Capital, LP also increased its position by 3 million shares, resulting in 3 million shares worth $56.7 million. Geode Capital Management, LLC added 2,495,399 shares, ending with 2,495,399 shares valued at about $47.17 million.

Definium Therapeutics Stock Snapshot

Shares of Definium Therapeutics (NASDAQ:DFTX) are trading around $24.75. The company has a market capitalization of approximately $2.7 billion. However, with negative earnings, it has no meaningful P/E ratio. The stock's beta is 2.378, indicating higher volatility compared to the market. It has a 52-week range between $6.345 and $26.25, with a 50-day moving average of $22.33 and a 200-day moving average of $15.99. The firm's current ratio is 4.692, and its quick ratio is 4.604, showing strong liquidity, while its debt-to-equity ratio stands at 14.622.

Recent Earnings

Definium Therapeutics is not currently profitable, reporting a negative earnings per share of -$2.50 and a return on equity of -94.7%. The company operates with a net margin of 0.0%, and its next earnings report is expected on July 30, 2026.

Insider Buying and Selling at Definium Therapeutics, Inc.

Recent insider activity at Definium Therapeutics includes several transactions. On March 25, 2026, Chief Legal Officer Mark Sullivan and Chief Medical Officer Daniel Karlin sold 10,702 and 8,018 shares, respectively, at an average price of $18.47 under pre-planned Rule 10b5-1 plans. CEO Robert Barrow also sold 24,431 shares on the same date. Earlier, on February 3, 2026, Barrow bought 320,000 shares, while Sullivan and Chief Commercial Officer Matthew Wiley purchased 125,000 and 115,000 shares, respectively, outside of any pre-planned arrangements.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Definium Therapeutics. Piper Sandler maintained a 'buy' rating with a price target of $48 on May 8, 2026. Leerink Partners also maintained a 'buy' rating with a $30 target on April 22, 2026. Other firms like Stifel, Canaccord Genuity, and HC Wainwright & Co. have similarly issued 'buy' ratings with targets ranging from $30 to $70. The analyst consensus remains a 'strong buy', with a mean target price of $39.87 from 15 analysts.

About Definium Therapeutics

Definium Therapeutics, Inc. is a New York-based clinical-stage biopharmaceutical company specializing in treatments for brain health disorders. The company is focused on developing innovative therapies, including its lead candidates DT120 and DT402, which are in advanced stages of clinical trials for conditions like anxiety, depression, and autism. Led by CEO Robert Barrow, Definium operates in the biotechnology sector with around 105 employees.

Bottom Line

Avoro Capital Advisors' new stake in Definium Therapeutics is a significant development, reflecting confidence in the company's future prospects. While the 13F filing provides a snapshot of past holdings, it may not represent Avoro's current position. Investors keep an eye on such filings to gauge institutional sentiment, even as they remember that these reports are backward-looking.